Cargando…
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
This article reviews the clinically most relevant presentations at the San Antonio Breast Cancer Symposium (SABCS) 2017 on the topics lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis. In a retrospective analysis of the Women’s Health Initiative Observatio...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132796/ https://www.ncbi.nlm.nih.gov/pubmed/30220928 http://dx.doi.org/10.1007/s12254-018-0433-x |
_version_ | 1783354387963314176 |
---|---|
author | Rinnerthaler, Gabriel Gampenrieder, Simon Peter Greil, Richard |
author_facet | Rinnerthaler, Gabriel Gampenrieder, Simon Peter Greil, Richard |
author_sort | Rinnerthaler, Gabriel |
collection | PubMed |
description | This article reviews the clinically most relevant presentations at the San Antonio Breast Cancer Symposium (SABCS) 2017 on the topics lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis. In a retrospective analysis of the Women’s Health Initiative Observational Study, a reduction in the body mass index (BMI) of at least 5% within 3 years significantly reduced the risk of breast cancer compared to women with a stable weight (HR 0.77; 95% CI 0.78–0.98). In the MONALEESA-7 trial investigating ribociclib or placebo in combination with endocrine therapy as first-line treatment in pre- and perimenopausal women with hormone receptor-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer, a significantly longer progression-free survival was shown for patients treated with ribociclib compared to the placebo group (23.8 vs. 13.0 months; HR 0.55; 95% CI 0.43–0.72; P < 0.001). In a pooled toxicity and efficacy analysis of elderly women treated with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in combination with an aromatase inhibitor in first-line, toxicities of higher grade were more common in elderly compared to younger patients, despite comparable efficacy. And the Clinical Treatment Score post-5 years (CTS5), accurately estimated the risk of late recurrence after 5 years of adjuvant endocrine treatment using routinely available clinical parameters. |
format | Online Article Text |
id | pubmed-6132796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-61327962018-09-13 SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis Rinnerthaler, Gabriel Gampenrieder, Simon Peter Greil, Richard Memo Short Review This article reviews the clinically most relevant presentations at the San Antonio Breast Cancer Symposium (SABCS) 2017 on the topics lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis. In a retrospective analysis of the Women’s Health Initiative Observational Study, a reduction in the body mass index (BMI) of at least 5% within 3 years significantly reduced the risk of breast cancer compared to women with a stable weight (HR 0.77; 95% CI 0.78–0.98). In the MONALEESA-7 trial investigating ribociclib or placebo in combination with endocrine therapy as first-line treatment in pre- and perimenopausal women with hormone receptor-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer, a significantly longer progression-free survival was shown for patients treated with ribociclib compared to the placebo group (23.8 vs. 13.0 months; HR 0.55; 95% CI 0.43–0.72; P < 0.001). In a pooled toxicity and efficacy analysis of elderly women treated with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in combination with an aromatase inhibitor in first-line, toxicities of higher grade were more common in elderly compared to younger patients, despite comparable efficacy. And the Clinical Treatment Score post-5 years (CTS5), accurately estimated the risk of late recurrence after 5 years of adjuvant endocrine treatment using routinely available clinical parameters. Springer Vienna 2018-08-21 2018 /pmc/articles/PMC6132796/ /pubmed/30220928 http://dx.doi.org/10.1007/s12254-018-0433-x Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Short Review Rinnerthaler, Gabriel Gampenrieder, Simon Peter Greil, Richard SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis |
title | SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis |
title_full | SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis |
title_fullStr | SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis |
title_full_unstemmed | SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis |
title_short | SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis |
title_sort | sabcs 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis |
topic | Short Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132796/ https://www.ncbi.nlm.nih.gov/pubmed/30220928 http://dx.doi.org/10.1007/s12254-018-0433-x |
work_keys_str_mv | AT rinnerthalergabriel sabcs2017lifestylefactorshormonereceptorpositiveadvanceddiseaseliquidbiopsiesandprognosis AT gampenriedersimonpeter sabcs2017lifestylefactorshormonereceptorpositiveadvanceddiseaseliquidbiopsiesandprognosis AT greilrichard sabcs2017lifestylefactorshormonereceptorpositiveadvanceddiseaseliquidbiopsiesandprognosis |